Newsletter Sign-Up

Keep up to date with NPC news and events by signing up for our e-newsletter E.V.I.dently, and our CER Daily Newsfeed.

Subscribe POLICY

NPC Survey of Health Care Stakeholders Indicates Cautious Optimism About Use of Comparative Effectiveness Research in Decision-Making

PCORI Growing in Importance, But AHRQ, NIH Still Lead on Research Standards, Funding

(Washington, DC, March 27, 2012)—A new survey of health care stakeholders shows that there is cautious optimism about the impact of comparative effectiveness research (CER) on health care decision-making and that recognition is continuing to grow for the Patient-Centered Outcomes Research Institute (PCORI)--the agency charged with overseeing this research. The 2012 survey, the second in an annual series conducted by the National Pharmaceutical Council, examined stakeholder opinion on CER and the current environment for health care decision-making.

“The findings reflect a more pragmatic view about how CER will be used and who will be funding it,” said NPC President Dan Leonard. “It’s clear from this second survey that stakeholders view CER with increasing importance, but they do not believe it has had a significant impact on health care decisions to date.”

Despite the growing recognition for PCORI’s role in CER, the Agency for Healthcare Research and Quality (AHRQ) and the National Institutes of Health (NIH) are viewed by surveyed stakeholders as the leading agencies for establishing priorities, and for funding and monitoring research. Stakeholders do expect PCORI to play an important role, however: although more than 80 percent of respondents believe that AHRQ will be influential in establishing research standards, 72 percent indicated a significant role for PCORI, compared to only 50 percent in the 2011 survey. Two-thirds of current respondents also expect PCORI to have an impact on establishing research priorities, and 60 percent note PCORI’s position in funding and monitoring research.  As for who will be doing the actual research—respondents believe that job will fall overwhelmingly (88 percent) to academics, with the pharmaceutical industry as their next choice (70 percent). Industry also is expected to play a significant role in funding and monitoring research, said two-thirds of respondents.

From 2011 to 2012, stakeholders who were surveyed indicated that they are slightly more optimistic about the momentum around CER yielding availability of new research methods (9 percent in 2011 to 14 percent in 2012) and agreed-upon standards for effectiveness research (10 percent to 14 percent). Stakeholders also thought that there was more transparency and objectivity in interpreting CER evidence (8 percent to 19 percent).

Stakeholders showed flat or lower expectations in other areas. They believe there is a lack of consistent and transparent standards for exchange of medical information (32 percent to 36 percent), and that there is a narrow focus on clinical effectiveness for treatment assessments without consideration of broader measures of value (26 percent to 39 percent).  Survey respondents also showed they were no more optimistic than a year ago that real-world research priorities reflect the choices patient and providers face (11 percent to 12 percent).

“It’s interesting that as the more granular issues have begun to emerge, we’re seeing that expectations for CER to impact health care decision-making are largely positive, but not universally rosy,” said Dr. Claudia Schur, director and vice president of the Center for Health Research & Policy at Social & Scientific Systems. “There are mixed expectations among stakeholders when it comes to the overall CER environment.”

The survey, conducted by Social & Scientific Systems on behalf of NPC, was fielded between October 2011 and February 2012 among key stakeholders impacted by CER, including government, researchers, insurers, employers, human resource consultants, health care coalitions, and trade and other groups. A total of 117 stakeholders participated.

View the complete survey results and instrument on NPC’s website.

About the National Pharmaceutical Council

The National Pharmaceutical Council is a health policy research organization dedicated to the advancement of good evidence and science and to fostering an environment in the United States that supports medical innovation. Founded in 1953 and supported by the nation’s major research-based pharmaceutical companies, NPC focuses on research, development, information dissemination, and education on the critical issues of evidence, innovation and the value of medicines for patients. For more information, visit www.npcnow.org and follow NPC on Twitter @npcnow.

###

Blog Post

#TBT: Expanding Your Horizons: CER Continuing Education Certificate Program

As part of our “Throwback Thursday” blog series, we’re taking a look at a topic that’s currently in the news and tagging it with previous...
Blog Post

CER Tweets of the Week: Improving Patient Care Remains Hot Topic (July 14 - 18)

Evidence-based medicine (EBM) and the role of big data in improving patient care continued to be hot topics among comparative effectiveness research...
Blog Post

CER Tweets of the Week: Patient-Generated Data, Value-Based Payment Programs & Impact of CER (July 7 - 11)

Which issues attracted comparative effectiveness research (CER) stakeholders’ attention this week in the Twitterverse? ...
Blog Post

#TBT: Consumer-Directed Health Plans & Employers’ Decision-Making

As part of our “Throwback Thursday” blog series, we’re taking a look at a topic that’s currently in the news and tagging it with previous...
Press Release

NPC Annual Stakeholder Survey: Comparative Effectiveness Research Is Important, But Impact on Health Care Decision-Making Is Still on the Horizon

(Washington, DC, May 19, 2014)—A new survey of health care stakeholders reveals continued optimism for the use of comparative effectiveness research...
Press Release

CER Collaborative Improving Health Outcomes Through New Comparative Evidence Tools

(Washington, DC, March 24, 2014)—Three peer-reviewed articles published in Value in Health offer important guidance to aid formulary decision-makers...
Press Release

NPC, Quintiles Study Tests Tools to Evaluate Quality of Observational Research in Comparative Effectiveness Studies

(Washington, DC, February 25, 2014)—With the growing demand for information about comparative effectiveness and questions about the quality of...
Press Release

Eli Lilly and Company Joins the National Pharmaceutical Council

Washington, D.C. (January 22, 2014)—The National Pharmaceutical Council (NPC) today announced that Eli Lilly and Company has joined the health care...
Commentary and Testimony Page

The State of CER and the Environment for Health Care Decision Making

This month, NPC released its third annual survey on stakeholders’ views on comparative effectiveness research (CER), “The State of Comparative...
Commentary and Testimony Page

Keeping Our Eye on the CER Ball

Until the cherry blossoms begin to bloom later next month, most of the water cooler conversations in Washington will focus on the federal budget....
Commentary and Testimony Page

Leveling the Playing Field? Could a Landmark Decision Alter the CER Communications Landscape?

A growing chorus of voices is publicly sharing data on the effectiveness of treatment options, but one viewpoint has long been shut out of key areas...
Commentary and Testimony Page

Living Up to Its Name? The Role of Patient-Centered Research

Anyone who has ever received bad news from his or her health care provider or held a loved one’s hand when a diagnosis was delivered can understand...
YouTube Videos

Real-World Impact of Comparative Effectiveness Research Findings on Clinical Practice

National Pharmaceutical Council Chief Science Officer Robert W. Dubois, MD, PhD, discusses a peer-reviewed study suggesting that changes are needed...
YouTube Videos

CER and the Environment for Health Care Decision-Making

The National Pharmaceutical Council’s (NPC) fourth annual survey of health care stakeholders is continuing to shed light on the current environment...
YouTube Videos

Webinar: CER Collaborative: Tools You Can Use

Collaborative members hosted a webinar explaining how to use the tools they developed to create greater uniformity and transparency when evaluating...
YouTube Videos

Use of Big and Real-World Data by Pharma: More than Data Warehousing

Real-world data—a subset of big data—is clinical data used for decision-making that did not come from a clinical trial. According to Aaron Galaznik,...
Blog Post

#TBT: Expanding Your Horizons: CER Continuing Education Certificate Program

As part of our “Throwback Thursday” blog series, we’re taking a look at a topic that’s currently in the news and tagging it with previous...
Blog Post

CER Tweets of the Week: Improving Patient Care Remains Hot Topic (July 14 - 18)

Evidence-based medicine (EBM) and the role of big data in improving patient care continued to be hot topics among comparative effectiveness research...
Blog Post

CER Tweets of the Week: Patient-Generated Data, Value-Based Payment Programs & Impact of CER (July 7 - 11)

Which issues attracted comparative effectiveness research (CER) stakeholders’ attention this week in the Twitterverse? ...
Blog Post

#TBT: Consumer-Directed Health Plans & Employers’ Decision-Making

As part of our “Throwback Thursday” blog series, we’re taking a look at a topic that’s currently in the news and tagging it with previous...

Research

  •  
  • 1 of 15
  • >

Commentary & Testimony